The alternative is to rely on the pharmaceutical company themselves to make an appropriate application to Pharmac. They haven't done that. The alternative then would be for each individual person who wanted a further dose to go through their doctor, to go through the named patient regime for off-label use. This process obviates the need for that and makes it available on a broad basis for those defined in the notice and for whom the director-general is satisfied there is a therapeutic benefit and for whom it is safe to further administer that dose. It is a very simple process in that respect. But, as members have raised in the debate in the House, this House can look forward to—and I know they will in eager anticipation—a recasting of our legislation that governs pharmaceuticals and medicines and other products claimed to have a therapeutic benefit, with the forthcoming therapeutic products bill. I can assure the House that there has been considerable work done—with, I might say, a sense of alacrity—and they won't have to wait too much longer. That bill is churning its way through.